Stop guessing which AI tool to use. Join AI Africa to discover tested AI tools, save your favourites, and use AI with a smile!
Free Account Ends Soon!
Access verified and curated tools
Bookmark tools for quick access
Get notified about new tools
What happens when one of the world's most powerful AI executives is discussing whether artificial intelligence should slow down and the US president suddenly calls him? You put him on speaker. That is exactly what happened on Monday at the All-In Summit in Los Angeles, where Nvidia CEO Jensen Huang was discussing the growing debate over AI safety when his phone started ringing. The caller? Donald Trump. Huang answered.
The AI world is asking one big question right now: Are we moving too fast? But US President Donald Trump appears to have a different priority: making sure China does not win the AI race. Speaking during a visit to Ireland on Sunday, Trump dismissed growing warnings about the dangers of rapidly developing artificial intelligence, arguing that some of the predictions are exaggerated.
The debate over how fast AI should develop has just become a lot more complicated. Anthropic CEO Dario Amodei recently called on the AI industry to slow the development of increasingly powerful AI systems, arguing that the technology is advancing faster than society’s ability to manage its risks. But China is not buying it. China’s state-backed Global Times has described Amodei’s proposal as a “Cold War playbook”
AI companies have spent years racing to build smarter and more powerful models. Now, one of the biggest names in the industry is saying something unexpected: Maybe they need to slow down. Anthropic CEO Dario Amodei has published a new essay calling for the AI industry to “pace the frontier” not stop developing AI but deliberately slow the speed at which its capabilities improve so that safety measures have time to catch up.
Imagine spending billions of dollars building some of the world's most powerful AI models only to discover that someone else may be repeatedly questioning your AI, collecting its answers, and using them to build a competing system. That is essentially the accusation now coming from the United States.
For a while, the AI race was mostly about one question: Who has the smartest model? Now, the question is changing. Who can actually make companies use AI successfully? Google Cloud appears to have an answer: send the experts directly to the companies. On September 8, Google Cloud and Accenture announced a new Accenture Gemini Enterprise Business Group, a joint initiative designed to help businesses move from experimenting with AI to actually deploying it across their operations.
Imagine paying $200 every month for Claude, barely using it, and then watching your AI allowance disappear. That is exactly what happened to one Claude subscriber in the UK. And the worrying part? He was not even using Claude when the tokens were being consumed.
Imagine telling an AI: “Book my trip, send the emails, lower my bills, and buy what I need.” Then closing your phone and letting it handle everything. That is the future Meta is betting on with Muse, its new personal AI agent. But there is a catch. For Muse to be genuinely useful, you have to give it access to some of the most personal parts of your digital life. And that raises a much bigger question than “How smart is the AI?”
What happens when one of the world’s hottest AI companies decides to go public? Wall Street is about to find out. Anthropic, the company behind the Claude AI chatbot, is preparing for a massive initial public offering that could value the company at around $2 trillion. If that happens, Anthropic would be entering the public market at a scale rarely seen before. But there is a small twist:
What if a drug designed to help damaged lungs could also make some of the body's biological signals look younger? That sounds like science fiction. But a new study published in Nature Biotechnology has given scientists a reason to take the idea seriously, although there is a very important catch. Researchers studying rentosertib, an experimental drug from AI-focused biotech company Insilico Medicine, found that patients who received the drug showed lower predicted biological ages
Explore